ConvaTec Group PLC (CNVVY)
12.90
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
ConvaTec Group Enterprise Value: 7.742B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 7.742B |
| May 30, 2024 | 7.742B |
| May 29, 2024 | 7.742B |
| May 28, 2024 | 7.742B |
| May 24, 2024 | 7.698B |
| May 23, 2024 | 7.660B |
| May 22, 2024 | 7.765B |
| May 21, 2024 | 7.753B |
| May 20, 2024 | 7.845B |
| May 17, 2024 | 7.994B |
| May 16, 2024 | 7.919B |
| May 15, 2024 | 7.963B |
| May 14, 2024 | 7.963B |
| May 13, 2024 | 7.963B |
| May 10, 2024 | 7.888B |
| May 09, 2024 | 7.666B |
| May 08, 2024 | 8.078B |
| May 07, 2024 | 7.864B |
| May 06, 2024 | 7.800B |
| May 03, 2024 | 7.800B |
| May 02, 2024 | 7.368B |
| May 01, 2024 | 7.509B |
| April 30, 2024 | 7.781B |
| April 29, 2024 | 7.600B |
| April 26, 2024 | 7.781B |
| Date | Value |
|---|---|
| April 25, 2024 | 8.099B |
| April 24, 2024 | 8.492B |
| April 23, 2024 | 8.450B |
| April 22, 2024 | 8.327B |
| April 19, 2024 | 8.411B |
| April 18, 2024 | 8.368B |
| April 17, 2024 | 8.342B |
| April 16, 2024 | 8.342B |
| April 15, 2024 | 8.406B |
| April 12, 2024 | 8.406B |
| April 11, 2024 | 8.478B |
| April 10, 2024 | 8.375B |
| April 09, 2024 | 8.355B |
| April 08, 2024 | 8.355B |
| April 05, 2024 | 8.578B |
| April 04, 2024 | 8.696B |
| April 03, 2024 | 8.862B |
| April 02, 2024 | 8.816B |
| April 01, 2024 | 8.698B |
| March 28, 2024 | 8.673B |
| March 27, 2024 | 8.673B |
| March 26, 2024 | 8.790B |
| March 25, 2024 | 8.596B |
| March 22, 2024 | 8.596B |
| March 21, 2024 | 8.714B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.428B
Minimum
Mar 18 2020
8.862B
Maximum
Apr 03 2024
6.520B
Average
6.505B
Median
Nov 27 2020
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 142.58M |
| Biodexa Pharmaceuticals Plc | 1.860M |
| Verona Pharma PLC | 772.32M |
| NuCana PLC | -8.064M |
| Autolus Therapeutics PLC | 356.16M |
Enterprise Value Related Metrics
| Earnings Yield | 1.95% |
| Operating Earnings Yield | 4.00% |
| Normalized Earnings Yield | 2.280 |